244 related articles for article (PubMed ID: 26872112)
21. Extended release metformin for metabolic control assistance during prolonged clozapine administration: a 14 week, double-blind, parallel group, placebo-controlled study.
Carrizo E; Fernández V; Connell L; Sandia I; Prieto D; Mogollón J; Valbuena D; Fernández I; de Baptista EA; Baptista T
Schizophr Res; 2009 Aug; 113(1):19-26. PubMed ID: 19515536
[TBL] [Abstract][Full Text] [Related]
22. Mitigation of Olanzapine-Induced Weight Gain With Samidorphan, an Opioid Antagonist: A Randomized Double-Blind Phase 2 Study in Patients With Schizophrenia.
Martin WF; Correll CU; Weiden PJ; Jiang Y; Pathak S; DiPetrillo L; Silverman BL; Ehrich EW
Am J Psychiatry; 2019 Jun; 176(6):457-467. PubMed ID: 30845818
[TBL] [Abstract][Full Text] [Related]
23. An exploration of the effect of modafinil on olanzapine associated weight gain in normal human subjects.
Roerig JL; Steffen KJ; Mitchell JE; Crosby RD; Gosnell BA
Biol Psychiatry; 2009 Apr; 65(7):607-13. PubMed ID: 19103435
[TBL] [Abstract][Full Text] [Related]
24. A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study.
McQuade RD; Stock E; Marcus R; Jody D; Gharbia NA; Vanveggel S; Archibald D; Carson WH
J Clin Psychiatry; 2004; 65 Suppl 18():47-56. PubMed ID: 15600384
[TBL] [Abstract][Full Text] [Related]
25. The effect of famotidine addition on olanzapine-induced weight gain in first-episode schizophrenia patients: a double-blind placebo-controlled pilot study.
Poyurovsky M; Tal V; Maayan R; Gil-Ad I; Fuchs C; Weizman A
Eur Neuropsychopharmacol; 2004 Aug; 14(4):332-6. PubMed ID: 15163444
[TBL] [Abstract][Full Text] [Related]
26. Metabolic effects of paliperidone extended release versus oral olanzapine in patients with schizophrenia: a prospective, randomized, controlled trial.
Schreiner A; Niehaus D; Shuriquie NA; Aadamsoo K; Korcsog P; Salinas R; Theodoropoulou P; Fernández LG; Uçok A; Tessier C; Bergmans P; Hoeben D
J Clin Psychopharmacol; 2012 Aug; 32(4):449-57. PubMed ID: 22722501
[TBL] [Abstract][Full Text] [Related]
27. Olanzapine-divalproex combination versus divalproex monotherapy in the treatment of bipolar mixed episodes: a double-blind, placebo-controlled study.
Houston JP; Tohen M; Degenhardt EK; Jamal HH; Liu LL; Ketter TA
J Clin Psychiatry; 2009 Nov; 70(11):1540-7. PubMed ID: 19778495
[TBL] [Abstract][Full Text] [Related]
28. Amantadine for weight gain associated with olanzapine treatment.
Deberdt W; Winokur A; Cavazzoni PA; Trzaskoma QN; Carlson CD; Bymaster FP; Wiener K; Floris M; Breier A
Eur Neuropsychopharmacol; 2005 Jan; 15(1):13-21. PubMed ID: 15572269
[TBL] [Abstract][Full Text] [Related]
29. Attenuation of olanzapine-induced weight gain with reboxetine in patients with schizophrenia: a double-blind, placebo-controlled study.
Poyurovsky M; Isaacs I; Fuchs C; Schneidman M; Faragian S; Weizman R; Weizman A
Am J Psychiatry; 2003 Feb; 160(2):297-302. PubMed ID: 12562576
[TBL] [Abstract][Full Text] [Related]
30. Reducing antipsychotic-induced weight gain in schizophrenia: a double-blind placebo-controlled study of reboxetine-betahistine combination.
Poyurovsky M; Fuchs C; Pashinian A; Levi A; Weizman R; Weizman A
Psychopharmacology (Berl); 2013 Apr; 226(3):615-22. PubMed ID: 23239133
[TBL] [Abstract][Full Text] [Related]
31. An 8-week, double-blind, randomized, placebo-controlled study of olanzapine long-acting injection in acutely ill patients with schizophrenia.
Lauriello J; Lambert T; Andersen S; Lin D; Taylor CC; McDonnell D
J Clin Psychiatry; 2008 May; 69(5):790-9. PubMed ID: 18452346
[TBL] [Abstract][Full Text] [Related]
32. Metformin for Treatment of Overweight Induced by Atypical Antipsychotic Medication in Young People With Autism Spectrum Disorder: A Randomized Clinical Trial.
Anagnostou E; Aman MG; Handen BL; Sanders KB; Shui A; Hollway JA; Brian J; Arnold LE; Capano L; Hellings JA; Butter E; Mankad D; Tumuluru R; Kettel J; Newsom CR; Hadjiyannakis S; Peleg N; Odrobina D; McAuliffe-Bellin S; Zakroysky P; Marler S; Wagner A; Wong T; Macklin EA; Veenstra-VanderWeele J
JAMA Psychiatry; 2016 Sep; 73(9):928-37. PubMed ID: 27556593
[TBL] [Abstract][Full Text] [Related]
33. Weight gain management in patients with schizophrenia during treatment with olanzapine in association with nizatidine.
Assunção SS; Ruschel SI; Rosa Lde C; Campos JA; Alves MJ; Bracco OL; de Lima MS
Braz J Psychiatry; 2006 Dec; 28(4):270-6. PubMed ID: 17242805
[TBL] [Abstract][Full Text] [Related]
34. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression.
Tohen M; Vieta E; Calabrese J; Ketter TA; Sachs G; Bowden C; Mitchell PB; Centorrino F; Risser R; Baker RW; Evans AR; Beymer K; Dube S; Tollefson GD; Breier A
Arch Gen Psychiatry; 2003 Nov; 60(11):1079-88. PubMed ID: 14609883
[TBL] [Abstract][Full Text] [Related]
35. Metformin for weight loss and metabolic control in overweight outpatients with schizophrenia and schizoaffective disorder.
Jarskog LF; Hamer RM; Catellier DJ; Stewart DD; Lavange L; Ray N; Golden LH; Lieberman JA; Stroup TS;
Am J Psychiatry; 2013 Sep; 170(9):1032-40. PubMed ID: 23846733
[TBL] [Abstract][Full Text] [Related]
36. Metformin for olanzapine-induced weight gain: a systematic review and meta-analysis.
Praharaj SK; Jana AK; Goyal N; Sinha VK
Br J Clin Pharmacol; 2011 Mar; 71(3):377-82. PubMed ID: 21284696
[TBL] [Abstract][Full Text] [Related]
37. Betahistine effects on weight-related measures in patients treated with antipsychotic medications: a double-blind placebo-controlled study.
Smith RC; Maayan L; Wu R; Youssef M; Jing Z; Sershen H; Szabo V; Meyers J; Jin H; Zhao J; Davis JM
Psychopharmacology (Berl); 2018 Dec; 235(12):3545-3558. PubMed ID: 30382354
[TBL] [Abstract][Full Text] [Related]
38. Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia.
Kinon BJ; Basson BR; Gilmore JA; Tollefson GD
J Clin Psychiatry; 2001 Feb; 62(2):92-100. PubMed ID: 11247108
[TBL] [Abstract][Full Text] [Related]
39. Adjunctive α-lipoic acid reduces weight gain compared with placebo at 12 weeks in schizophrenic patients treated with atypical antipsychotics: a double-blind randomized placebo-controlled study.
Kim NW; Song YM; Kim E; Cho HS; Cheon KA; Kim SJ; Park JY
Int Clin Psychopharmacol; 2016 Sep; 31(5):265-74. PubMed ID: 27276401
[TBL] [Abstract][Full Text] [Related]
40. Safety and efficacy of olanzapine monotherapy and olanzapine with a mood stabilizer in 18-week treatment of manic/mixed episodes for Japanese patients with bipolar I disorder.
Katagiri H; Takita Y; Tohen M; Higuchi T; Kanba S; Takahashi M
Curr Med Res Opin; 2012 May; 28(5):701-13. PubMed ID: 22356118
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
